White matter

Imeka Receives FDA 510(k) Clearance for ANDI Medical Device

Retrieved on: 
Monday, July 31, 2023
Myenteric plexus, Diffusion, Brain, Neurology, ANDI, Radiology, MRI, Map, Algorithm, AMA, White matter, Diagnosis, PDF, FDA, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, QC

SHERBROOKE, QC, July 31, 2023 /PRNewswire/ -- Imeka, the leading neuroimaging company combining diffusion imaging and AI to map white matter microstructure, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Advanced Neuro Diagnostic Imaging (ANDI) quantitative imaging software. The report generated by ANDI provides medical professionals, including but not limited to neurologists and radiologists, with important reference information on brain white matter as an adjunct to care.

Key Points: 
  • The report generated by ANDI provides medical professionals, including but not limited to neurologists and radiologists, with important reference information on brain white matter as an adjunct to care.
  • Imeka is pioneering AI in diffusion MRI-based white matter imaging to evaluate microstructural properties of white matter in greater detail than any other techniques," said Jean-René Bélanger, Chief Executive Officer at Imeka.
  • The device processes diffusion-weighted images using reconstruction algorithms called modeling, tractography, and fiber bundling to map microstructural properties of the white matter.
  • "With ANDI, we're unlocking important information in brain white matter tracts that can assist radiologists, neurologists, and other medical professionals in providing high-quality, efficient patient care."

Neurophet to unveil brain image analysis technology related to treatment of Alzheimer's disease at AAIC 2023

Retrieved on: 
Tuesday, July 18, 2023
Bleeding, Myenteric plexus, Atrophy, Digital, GRE, Edema, SWI, PET, Prognosis, Brain, Biomarker, Medicare, MRI, ARIA, AAIC, Artificial intelligence, Observation, Diagnosis, White matter, Conference, Amyloid, Medical imaging, Alzheimer's disease, Patient

SEOUL, South Korea, July 18, 2023 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the Alzheimer's Association International Conference (AAIC) 2023, which is held in Amsterdam, Netherlands.

Key Points: 
  • At this conference, Neurophet has showcased brain MRI analysis software "Neurophet AQUA", and brain PET scan analysis software "Neurophet SCALE PET".
  • Especially Neurophet has introduced the latest brain image analysis technology that can be used in the field of clinical trials and prescription of new drugs for Alzheimer's disease.
  • Neurophet AQUA is a brain MRI analysis software that analyzes brain atrophy observed in neurodegenerative diseases such as Alzheimer's disease.
  • "We are going all out to develop solutions related to Alzheimer's disease treatment to preemptively target the high-growth Alzheimer's disease treatment market."

Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease

Retrieved on: 
Monday, July 17, 2023
Hardware, FDA, Data Management, Other Health, Technology, Pharmaceutical, Medical Devices, Seniors, Clinical Trials, Biotechnology, Science, Software, Other Science, Consumer, Research, Health, Atrophy, Nerve, Brain, CNS, Dementia, MRI, ARIA, M.D, AAIC, Patient, White matter, AD, Therapy, MMSE, Conference, Medical imaging, Cognito

“Our Phase 2 study demonstrated that Cognito’s proprietary disease-modifying therapy reduced brain atrophy and myelin loss in Alzheimer’s patients.

Key Points: 
  • “Our Phase 2 study demonstrated that Cognito’s proprietary disease-modifying therapy reduced brain atrophy and myelin loss in Alzheimer’s patients.
  • Daily use of the Gamma Sensory Stimulation System was confirmed to be safe with minimal side effects.
  • “Our Phase 2 OVERTURE study results continue to demonstrate that daily, proprietary gamma sensory stimulation is safe and well tolerated,” said Brent Vaughan, CEO, Cognito Therapeutics.
  • “Patients in the active arm demonstrated a reduction in decline in functional and cognitive abilities, and showed reduced brain atrophy.

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

Retrieved on: 
Tuesday, July 11, 2023
GFAP, Grey, CNS Drugs (journal), Pathology, Brain, Biomarker, Inflammation, CNS, Dementia, MRI, AAIC, Amyloid, Cortex, Patient, Risk, Drug development, White matter, Conference, MMSE, Disease, Medical imaging

Boca Raton, Florida, July 11, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reveals new findings from data to be presented at the annual Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands. AAIC is the largest medical meeting focused on Alzheimer’s Disease (AD).

Key Points: 
  • INmune Bio is a pioneer in the use of novel microstructural neuroimaging biomarkers to measure pharmacodynamic activity of treatment with XProTM in patients with AD.
  • The results demonstrate a dose dependent enhancement in gray matter measures throughout the brain in AD patients treated with XProTM.
  • CDM® is a novel gray matter measure that is more effective than standard whole brain volumetric changes in predicting cognitive decline.
  • Notably, the greatest improvement was observed in the gray matter of brain regions where Alzheimer’s disease originates.

BrainTale Has Presented at the European Academy of Neurology and the World Parkinson Congress the Interest of Its Digital Biomarker Platform for the Early and Differential Diagnosis of Parkinson's Disease

Retrieved on: 
Friday, July 7, 2023
Health, Neurology, General Health, Research, Science, Pharmaceutical, Biotechnology, EAN, CET, PD, Hospital, Ageing, European Academy of Neurology, Multiple system atrophy, Brain, Biomarker, Incidence, Neuroscience, Professor, Parkinson's disease, Patient, Myenteric plexus, Neuroradiology, Parkinsonism, White matter, Diffusion, Basal ganglia, Tauopathy, PSP, Disease, Medical imaging

Vincent Perlbarg, co-founder, scientific director and president of BrainTale, has presented the results supporting the interest of BrainTale’s digital biomarker platform for the care of patients suffering from the disease and the development of new therapies.

Key Points: 
  • Vincent Perlbarg, co-founder, scientific director and president of BrainTale, has presented the results supporting the interest of BrainTale’s digital biomarker platform for the care of patients suffering from the disease and the development of new therapies.
  • Accordingly, since its creation in 2018, BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases.
  • These preliminary data highlight the relevance and sensitivity of BrainTale’s white matter biomarkers to Parkinsonian syndromes, including early stages of Parkinson's disease.
  • The entire BrainTale team is highly committed to providing our solutions to all stakeholders," adds Vincent Perlbarg, co-founder, president and Chief Scientific Officer of the company.

CraniUS obtains scientific evidence of successful convection-enhanced delivery using patented NeuroPASS device

Retrieved on: 
Tuesday, June 27, 2023
Gadolinium, Myenteric plexus, Human, Radiology, Neuroscience, Traffic barrier, Medicine, Brain, Catheter, Scalp, Convection, MRI, Animal, Johns Hopkins University, Patient, White matter, FDA, IND, Medical device, Medical imaging, Pharmaceutical industry, MD, Neurosurgery

BALTIMORE, Md., June 27, 2023 /PRNewswire/ -- CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain diseases, announces the scientific findings of successful convection-enhanced delivery in their pre-clinical study investigating the company's patented NeuroPASS device.

Key Points: 
  • CraniUS becomes the first company with a smart, refillable, and fully embedded medical device that effectively bypasses the blood-brain barrier and achieves long-term, convection-enhanced medicine delivery.
  • BALTIMORE, Md., June 27, 2023 /PRNewswire/ -- CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain diseases, announces the scientific findings of successful convection-enhanced delivery in their pre-clinical study investigating the company's patented NeuroPASS device.
  • NeuroPASS provides a potentially safe alternative to systemic drug delivery for brain disease at a lower dosage with easy access for refilling.
  • "What CraniUS has built, and now tested successfully, in their large animal study is without question a quantum leap forward for our field.

Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2023

Retrieved on: 
Monday, June 26, 2023
Research, Seniors, Neurology, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Consumer, Health, Science, Cognito, Atrophy, Alzheimer's disease, HOPE, CNS, AAIC, Patient, Randomness, Physiology, White matter, FDA, Therapy, Conference, Axon, Disease, Pharmaceutical industry, Medical imaging

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced that it will present four scientific abstracts at the Alzheimer’s Association International Conference 2023 (AAIC).

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced that it will present four scientific abstracts at the Alzheimer’s Association International Conference 2023 (AAIC).
  • The largest international meeting dedicated to advancing dementia science, AAIC will be held in Amsterdam, Netherlands and online from July 16-20, 2023.
  • MHSc, Chief Medical Officer, Cognito Therapeutics.
  • Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders.

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Retrieved on: 
Tuesday, June 20, 2023
Medical Devices, Health, Neurology, Health Technology, Pharmaceutical, Biotechnology, Drug development, Adrenoleukodystrophy, Professor, ALD, ESPCI, Hospital, Medical physics, Ageing, DSM-IV codes, Software, Multimedia, Brain, Engineer, Biomarker, Doctor of Philosophy, Harvard University, Intensivist, MRI, Alzheimer's disease, Parkinson's disease, Magnetic resonance imaging, Neuroscience, Patient, Myenteric plexus, Physician, Coma, Observation, White matter, Diagnosis, ALS, Pharmaceutical industry, Medical imaging, Software as a service, Neuroradiology, Atlantic Ocean

To explore this new continent of the brain, BrainTale is developing a measurement solution that improves diagnosis, monitoring and prediction with a non-invasive, pain-free, efficient and clinically validated approach.

Key Points: 
  • To explore this new continent of the brain, BrainTale is developing a measurement solution that improves diagnosis, monitoring and prediction with a non-invasive, pain-free, efficient and clinically validated approach.
  • "This fundraising is a decisive step for BrainTale, and enables us to look forward with ambition to our next development milestones.
  • BrainTale improves the practice of healthcare professionals and the quality of care by improving the prediction of neurological diseases such as Alzheimer's and Parkinson's diseases.
  • This round of financing will enable BrainTale to enter a new phase in its development," states Sébastien Couvet, head of the MACSF Group's e-health portfolio.

A Chinese Neurosurgical Journal Study Presents Consensus on the Management of Aneurysmal Subarachnoid Hemorrhage-Related Hydrocephalus

Retrieved on: 
Tuesday, June 13, 2023
Nerve, Drainage, Aneurysm, Shunt (electrical), Quality of life, Brain, Risk, Ambiguity, Cerebrospinal fluid, History, Research, Interventional Neuroradiology, Literature, Subarachnoid hemorrhage, Intracranial pressure, Jugular vein, CSF, Hydrocephalus, Diagnosis, White matter, Capital Medical University, Intraventricular hemorrhage, Medical device

BEIJING, June 13, 2023 /PRNewswire/ -- Aneurysmal subarachnoid hemorrhage-related hydrocephalus (aSAH-H) is a clinical syndrome that leads to excessive accumulation of cerebrospinal fluid (CSF) and ventricle enlargement in the brain. aSAH-H is a complex pathophysiological syndrome, leadingto cognitive impairment and neurological damage. Acute hydrocephalus (less than 3 days of aSAH) can result in a fatal cerebral hernia, whereas chronic hydrocephalus (more than 3 days of aSAH) can adversely affect a patient's quality of life.

Key Points: 
  • Despite the complexity of this condition, there is a lack of diagnostic criteria and treatment protocol for aSAH-H, in China and abroad.
  • Moreover, the lack of consensus among clinicians on the preferred treatment for aSAH-H calls for an urgent need for consistent standards.
  • The study was published in volume 9 of the Chinese Neurosurgical Journal on March 20, 2023.
  • Furthermore, the consensus guideline recommends external ventricular drainage and ensuring the safe removal of the CSF drainage tube in the case of acute hydrocephalus.

The Flomenhaft Law Firm, PLLC wins hallmark brain imaging litigation discovery victory before the Supreme Court of the State of New York Appellate Division, First Judicial Department

Retrieved on: 
Thursday, June 8, 2023
Class Action Lawsuit, Professional Services, Legal, White matter, Montefiore Medical Center, Diffusion MRI, Communication, MRI, DTI, Principal, Supreme court, Medical imaging, PLLC

The Flomenhaft Law Firm, PLLC, www.brainjusticeny.com , won a hallmark victory before the Supreme Court of the State of New York Appellate Division, First Judicial Department in Almonte v. Con Edison Company of New York, Inc., Index No.

Key Points: 
  • The Flomenhaft Law Firm, PLLC, www.brainjusticeny.com , won a hallmark victory before the Supreme Court of the State of New York Appellate Division, First Judicial Department in Almonte v. Con Edison Company of New York, Inc., Index No.
  • The appellate panel reversed the order of the trial court requiring production of various technical data supporting Diffusion Tensor Imaging (“DTI”).
  • DTI is a special sequence of brain MRI used to detect white matter abnormalities.
  • The brain’s white matter furnishes the communication network among the brain’s approximately eight- six billion brain cells.